DRAGANA TRIVUNOVIC: Open Payments
NPI 1851964894 · VALPARAISO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,594 in 185 payments from 24 companies in 2025. Trend: 2023 $869 · 2024 $2,262 · 2025 $8,594
Speaker / faculty: $5,000Food & beverage: $3,479Consulting: $115
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $5,179 |
| Vanda Pharmaceuticals Inc. | 11 | $384 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $287 |
| Neurocrine BioSciences, Inc. | 11 | $254 |
| E.R. Squibb & Sons, L.L.C. | 15 | $240 |
| Lundbeck LLC | 13 | $220 |
| Otsuka America Pharmaceutical, Inc. | 11 | $214 |
| Supernus Pharmaceuticals, Inc. | 21 | $202 |
| Tris Pharma Inc | 10 | $190 |
| Alkermes, Inc. | 13 | $182 |
Products named: VRAYLAR, FANAPT, REXULTI, CAPLYTA, INGREZZA, SPRAVATO, COBENFY, Qelbree.
Industry payments across IN — which companies pay providers there.
